Ora Names Thermo Fisher Executive as General Counsel

Ora has welcomed a new member to its C-Suite, appointing Henry (Hank) Gerock III as general counsel.

“Clinical trial contracting can be complex—especially when involving cutting-edge therapies and multi-country studies. With Hank’s appointment, Ora is reinforcing its commitment to delivering a seamless, efficient legal experience for its clients, enabling them to focus on what matters most: bringing life-changing therapies to patients across the globe,” Ora CEO Paul Colvin stated.

A seasoned legal executive, Gerock has extensive expertise in international business transactions, regulatory and compliance matters, dispute resolution, and corporate governance. He most recently served as general counsel of the Clinical Research Group (formerly PPD) at Thermo Fisher Scientific Inc., where he led a global legal team supporting large-scale contract research organization (CRO) operations.

In his new role at Ora, Gerock will focus on accelerating legal and contracting processes, enhancing client engagement, and driving operational efficiencies. His global perspective and proven track record of problem-solving will be instrumental in supporting Ora’s mission to deliver ophthalmology clinical trials with speed, precision, and excellence worldwide.

Ora is a full-service ophthalmic drug and device CRO with employees in more than 20 countries worldwide. For over 50 years, the company has helped clients earn more than 85 product approvals. Ora supports a wide array of innovators and organizations, from startups to global pharmaceutical and device companies, to efficiently bring new products from concept to market. Ora’s clinical models, methodologies, and global regulatory strategies have been refined and proven across thousands of global projects.